{"disease":{"id":"parathyroid-carcinoma","name":"parathyroid carcinoma"},"drugs":{"marketed":[{"drug_id":"evocalcet","indication_name":"Hypercalcemia in parathyroid carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Orkedia","generic_name":"EVOCALCET","company_name":"Kyowa Hakko Kirin Co., Ltd.","drug_phase":"marketed","molecular_target":"Extracellular calcium-sensing receptor","drug_class":"","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"cinacalcet","indication_name":"Parathyroid Carcinoma with Hypercalcemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sensipar","generic_name":"CINACALCET","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Extracellular calcium-sensing receptor","drug_class":"Calcium-sensing Receptor Agonist","quality_score":65,"revenue":null,"mechanism":"Sensipar works by activating the calcium-sensing receptor, which helps regulate calcium levels in the blood."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06852144","title":"PET-TC in Thyroid Evaluation","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":418,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT03039439","title":"Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":310,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06645951","title":"Institution of an Italian Multicenter Database of Patients with Parathyroid Carcinoma or Atypical Parathyroid Adenoma","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore","has_results":false},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT03046524","title":"Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristics and Biological Behavior","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07475780","title":"Radiofrequency Ablation For Recurrent Parathyroid Carcinoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03280264","title":"Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Kyowa Kirin Co., Ltd.","has_results":true},{"nct_id":"NCT04106843","title":"Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}